Scholars@Duke

Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.

Publication ,  Journal Article
Corey, GR; Kollef, MH; Shorr, AF; Rubinstein, E; Stryjewski, ME; Hopkins, A; Barriere, SL
Published in: Antimicrob Agents Chemother
June 2014
Published version (DOI) Link to item

Duke Scholars

Gordon Ralph Corey
Author Gordon Ralph Corey Medicine, Infectious Diseases

Published In

Antimicrob Agents Chemother

DOI

10.1128/AAC.02899-14

EISSN

1098-6596

Publication Date

June 2014

Volume

58

Issue

6

Start / End Page

3581

Location

United States

Related Subject Headings

  • Microbiology
  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology
  • 3107 Microbiology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1108 Medical Microbiology
  • 0605 Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Corey, G. R., Kollef, M. H., Shorr, A. F., Rubinstein, E., Stryjewski, M. E., Hopkins, A., & Barriere, S. L. (2014). Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother, 58(6), 3581. https://doi.org/10.1128/AAC.02899-14
Corey, G. R., M. H. Kollef, A. F. Shorr, E. Rubinstein, M. E. Stryjewski, A. Hopkins, and S. L. Barriere. “Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.” Antimicrob Agents Chemother 58, no. 6 (June 2014): 3581. https://doi.org/10.1128/AAC.02899-14.
Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014 Jun;58(6):3581.
Corey, G. R., et al. “Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.” Antimicrob Agents Chemother, vol. 58, no. 6, June 2014, p. 3581. Pubmed, doi:10.1128/AAC.02899-14.
Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014 Jun;58(6):3581.

Published In

Antimicrob Agents Chemother

DOI

10.1128/AAC.02899-14

EISSN

1098-6596

Publication Date

June 2014

Volume

58

Issue

6

Start / End Page

3581

Location

United States

Related Subject Headings

  • Microbiology
  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology
  • 3107 Microbiology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1108 Medical Microbiology
  • 0605 Microbiology